These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579 [TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. Jaeger U; Worel N; McGuirk JP; Riedell PA; Fleury I; Du Y; Han X; Pearson D; Redondo S; Waller EK Blood Adv; 2023 Jun; 7(11):2283-2286. PubMed ID: 36044388 [TBL] [Abstract][Full Text] [Related]
16. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Mueller KT; Maude SL; Porter DL; Frey N; Wood P; Han X; Waldron E; Chakraborty A; Awasthi R; Levine BL; Melenhorst JJ; Grupp SA; June CH; Lacey SF Blood; 2017 Nov; 130(21):2317-2325. PubMed ID: 28935694 [TBL] [Abstract][Full Text] [Related]
17. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370 [TBL] [Abstract][Full Text] [Related]
18. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Maziarz RT; Zhang J; Yang H; Chai X; Yuan C; Schwarz E; Jakovac M; Martinez-Prieto M; Agarwal A; Degtyarev E; Tam C; Salles G Blood Adv; 2022 Apr; 6(8):2536-2547. PubMed ID: 35030634 [TBL] [Abstract][Full Text] [Related]
19. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Bao F; Wan W; He T; Qi F; Liu G; Hu K; Lu XA; Yang P; Dong F; Wang J; Jing H Cancer Gene Ther; 2019 Jul; 26(7-8):248-255. PubMed ID: 30622321 [TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]